Why are vaccines so hard to make? The fda approved two mRNA vaccines for COVID-19, but it was a challenge to make this type ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported.

A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

The open-label, multi-part Phase II trial will assess RCT2100’s biodistribution, safety, and tolerability via oral inhalation ...

Restoring P53's autonomous anti-cancer function through P53 mRNA delivery is a promising anti-tumor strategy. Yet, in tumors harboring mutant P53, the existing mutant P53 (Mutp53) would interferes ...

CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in ...

RNA plays a vital role in how our genes are expressed and how diseases develop. Yet, because RNA molecules constantly change ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel highlighted various alleged “safety uncertainties” of the mRNA COVID-19 ...